We are live on
!
Find out more
RJA
Raymond James & Associates Portfolio holdings
AUM
$164B
1-Year Est. Return
33.91%
This Fund
S&P 500
This Quarter
Est. Return
+2.33%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$152B
AUM Growth
+$4.77B
(+3.2%)
Cap. Flow
+$2.89B
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
26.78%
Holding
4,133
New
185
Increased
1,882
Reduced
1,701
Closed
184
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$255M |
| 2 |
Apple
AAPL
|
+$184M |
| 3 |
NextEra Energy
NEE
|
+$153M |
| 4 |
Walmart Inc
WMT
|
+$141M |
| 5 |
Public Service Enterprise Group
PEG
|
+$119M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$157M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$110M |
| 3 |
NVIDIA
NVDA
|
+$90.1M |
| 4 |
Vistra
VST
|
+$72.2M |
| 5 |
Union Pacific
UNP
|
+$58.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.11% |
| 2 | Financials | 8.61% |
| 3 | Healthcare | 7.69% |
| 4 | Industrials | 6.49% |
| 5 | Consumer Discretionary | 5.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3826
Lineage Cell Therapeutics
LCTX
$286M
| $25.7K | ﹤0.01% |
25,726
+5,539
| +27% | +$6.12K |
|
|
SERV
3827
Serve Robotics
SERV
$427M
| $25.5K | ﹤0.01% |
+13,096
| New | +$35.2K |
|
|
DHY
3828
Credit Suisse High Yield Credit Fund
DHY
$243M
| $24.2K | ﹤0.01% |
12,000
| – | – |
|
|
AMRN
3829
Amarin Corp
AMRN
$298M
| $24K | ﹤0.01% |
1,744
+16
| +0.9% | +$275 |
|
3830
W&T Offshore
WTI
$577M
| $22.9K | ﹤0.01% |
+10,715
| New | +$24.9K |
|
3831
BioXcel Therapeutics
BTAI
$28.7M
| $22.7K | ﹤0.01% |
1,108
-50
| -4% | -$1.67K |
|
3832
Solid Power
SLDP
$536M
| $22.7K | ﹤0.01% |
13,750
-2,600
| -16% | -$4.49K |
|
3833
Veru
VERU
$44.5M
| $22.7K | ﹤0.01% |
+2,696
| New | +$31.2K |
|
|
VISN
3834
Vistance Networks Inc
VISN
$2.63B
| $22.6K | ﹤0.01% |
18,398
-13,970
| -43% | -$16.6K |
|
3835
CEL-SCI Corp
CVM
$26M
| $21.9K | ﹤0.01% |
629
| – | – |
|
3836
LanzaTech
LNZA
$70.1M
| $21.3K | ﹤0.01% |
+115
| New | +$29.3K |
|
3837
POET Technologies
POET
$1.48B
| $20.9K | ﹤0.01% |
10,100
| – | – |
|
3838
Dawson Geophysical
DWSN
$131M
| $20.7K | ﹤0.01% |
10,593
| – | – |
|
3839
Ginkgo Bioworks
DNA
$515M
| $20.6K | ﹤0.01% |
1,538
-2,921
| -66% | -$87.2K |
|
|
CMRX
3840
DELISTED
Chimerix, Inc.
CMRX
| $20.3K | ﹤0.01% |
23,200
-20,000
| -46% | -$19K |
|
|
SOHO
3841
DELISTED
Sotherly Hotels
SOHO
| $19.1K | ﹤0.01% |
16,650
| – | – |
|
3842
Stereotaxis
STXS
$143M
| $18.8K | ﹤0.01% |
+10,350
| New | +$23.2K |
|
3843
SES AI
SES
$196M
| $18.8K | ﹤0.01% |
+15,000
| New | +$20.4K |
|
3844
Lexicon Pharmaceuticals
LXRX
$1.07B
| $18.3K | ﹤0.01% |
10,912
+71
| +0.7% | +$127 |
|
3845
Hyliion Holdings
HYLN
$701M
| $18K | ﹤0.01% |
11,100
| – | – |
|
3846
Outdoor Holding Co
POWW
$297M
| $17.7K | ﹤0.01% |
10,528
| – | – |
|
3847
LivePerson
LPSN
$31.2M
| $16.8K | ﹤0.01% |
1,924
-16
| -0.8% | -$154 |
|
3848
BlackSky Technology
BKSY
$1.17B
| $16.6K | ﹤0.01% |
1,945
-904
| -32% | -$8.48K |
|
3849
Cognition Therapeutics
CGTX
$99.8M
| $16.6K | ﹤0.01% |
10,000
| – | – |
|
3850
CALL
VanEck Pharmaceutical ETF
PPH
$1B
| $16.4K | ﹤0.01% |
+200
| New | +$17.9K |
|
Similar funds
RJFSA
PI
ECU
EAM
AA
SA
WPL
ECU
Raymond James & Associates's Q2 2024 Portfolio in Review
As of Q2 2024, Raymond James & Associates held 4,133 positions worth $152B, up 3.2% from $148B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Raymond James & Associates's Q2 2024 filing shows 185 new, 1,882 increased, 1,701 reduced and 184 closed positions. Its largest new stake was Solventum: 321,226 shares worth $17M. The largest sale was State Street Health Care Select Sector SPDR ETF, an estimated $157M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.
- Raymond James & Associates's largest Q2 2024 buy was Solventum: 321,226 shares worth $17M.
- Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q2 2024, an estimated $255M increase.
- Raymond James & Associates's biggest Q2 2024 reduction was State Street Health Care Select Sector SPDR ETF, cutting an estimated $157M.
- Raymond James & Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $110M.
- Raymond James & Associates's ten largest holdings make up 27% of its $152B portfolio in Q2 2024.
- Raymond James & Associates opened 185 new positions and closed 184 in Q2 2024.
- Raymond James & Associates's portfolio value rose 3.2% quarter-over-quarter to $152B.
Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.